Returns Chart

Key Stats

Customize
Expense Ratio Total Assets Under Management Dividend Yield Turnover Ratio
1.25% 317.46M 0.51% 74.60%
1 Year Fund Level Flows 1 Year Total Returns (Daily) Annualized All Time Total Returns (Daily) Max Drawdown (All)
-14.37M 12.10% Upgrade Upgrade

Basic Info

Investment Strategy
The Class aims to provide long-term capital growth by investing in the common shares of global corporations engaged in the development, production or distribution of products and services related to the treatment or prevention of medical diseases or other medical related problems.
General
Security Type Mutual Fund
Oldest Share Symbol IGI262
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index Morningstar Gbl Mkts GR CAD
Prospectus Objective --
Fund Owner Firm Name Investors Group Inc
Prospectus Benchmark Index
MSCI World (Net) CAD Benchmark 100.0%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Eric Ng 0.75 yrs
Lawrence(Larry) Llaguno 0.75 yrs
ZiJian (Richard) Zhu 0.75 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 87
-14.37M
-338.90M Category Low
449.74M Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of April 30, 2022

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of May 20, 2022. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
23.16%
-8.91%
10.25%
7.58%
16.23%
12.89%
20.34%
-6.09%
-7.76%
21.36%
9.78%
-7.58%
21.93%
5.56%
28.04%
-4.04%
--
--
--
12.27%
13.01%
8.43%
18.97%
-6.72%
--
--
--
--
--
--
16.44%
0.12%
15.42%
-18.25%
7.66%
2.23%
13.15%
13.23%
0.15%
-8.64%
As of May 20, 2022.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-20-22) 0.51%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 19.73
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of February 28, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of February 28, 2022

Asset Allocation

As of February 28, 2022.
Type % Net % Long % Short
Cash 0.31% Upgrade Upgrade
Stock 99.59% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.10% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Johnson & Johnson 6.95% 179.47 1.41%
UnitedHealth Group Inc 6.23% 492.09 1.31%
AbbVie Inc 4.84% 148.01 -1.99%
Pfizer Inc 4.47% 52.86 0.74%
Roche Holding AG
4.10% -- --
Abbott Laboratories 3.88% 115.10 1.64%
Thermo Fisher Scientific Inc 3.78% 555.33 0.03%
Merck & Co Inc 2.89% 93.85 0.32%
Amgen Inc 2.88% 248.97 0.59%
Anthem Inc 2.61% 494.62 0.36%

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee Upgrade
Administration Fee Upgrade
Performance Fee --
Switching Fee Upgrade
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP Yes
Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment Upgrade
Minimum Subsequent Investment Upgrade

Basic Info

Investment Strategy
The Class aims to provide long-term capital growth by investing in the common shares of global corporations engaged in the development, production or distribution of products and services related to the treatment or prevention of medical diseases or other medical related problems.
General
Security Type Mutual Fund
Oldest Share Symbol IGI262
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index Morningstar Gbl Mkts GR CAD
Prospectus Objective --
Fund Owner Firm Name Investors Group Inc
Prospectus Benchmark Index
MSCI World (Net) CAD Benchmark 100.0%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Eric Ng 0.75 yrs
Lawrence(Larry) Llaguno 0.75 yrs
ZiJian (Richard) Zhu 0.75 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-20-22) 0.51%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 19.73
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of February 28, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of February 28, 2022

Fund Details

Key Dates
Inception Date 7/12/2013
Last Annual Report Date 3/31/2021
Last Prospectus Date --
Share Classes
IGI1122 Commission-based Advice
IGI1123 Commission-based Advice
IGI262 Commission-based Advice
IGI263 Commission-based Advice
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

Top Portfolio Holders

0 of 0